Canna-V-Cell

  • ISIN: CA13767B1013
  • Land: .

Nachricht vom 14.08.2019 | 02:13

Canna-V-Cell Sciences Inc. Announces Private Placement

DGAP-News: Canna-V-Cell / Key word(s): Miscellaneous

14.08.2019 / 02:13
The issuer is solely responsible for the content of this announcement.


Vancouver, British Columbia--(Newsfile Corp. - August 13, 2019) - Canna-V-Cell Sciences Inc. (CSE: CNVC) (the "Company") announces that the Company intends to complete a private placement of up to 6,666,667 units at a price $0.15 per unit for total proceeds of up to $1,000,000. Each unit will consist of one common share of the Company and one non-transferable share purchase warrant. Each warrant will be exercisable to purchase an additional common share at a price of $.30 per share for a period of four years from closing of the private placement.

The Company will pay commissions of 5% to registered investment dealers and brokers or to finders in jurisdictions where permitted by law.

With the completion of the development program well in sight, the Company is turning its attention to the next important steps in order to fulfill its full potential. To this end, the Company will use the funds to expand R&D; to plan for manufacturing and production of Cannabis cells powder based on the breakthrough biofarming technology. In addition, the Company wishes to reinforce its business development activities to reach potential customers and partners.

About Canna-V-Cell Sciences Inc.

Based in Vancouver BC, Canna-V-Cell Sciences Inc. (CNVC) is the exclusive Cannabis worldwide licensee of the proprietary and patent protected BioHarvest technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. By adopting this technology and building adequate cells production capacity, Canna-V-Cell's objective is to become the leading supplier of Cannabis for both the medicinal and recreational legal use.

Canna-V-Cell Sciences Inc.
Dr. Zaki Rakib
CEO

For further information, please contact:
Dave Ryan, President & Director
Phone: 1 (604) 622-1186
Email: dave.ryan@cannavcell.com

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things, risks and uncertainties relating to the fact that the Company would require additional funds in order to construct a commercial biochamber facility and risks related to the adaption of the BioHarvest technology to cannabis. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46920

Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/46920


14.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

HanseYachts: „Der ideale Zeitpunkt für den Kauf“

Die Übernahme des Katamaran-Herstellers Privilège bringt die HanseYachts AG dem Umsatzziel von 200 Mio. Euro einen bedeutenden Schritt näher. „Der Katamaran-Markt ist das derzeit am stärksten wachsende Segment im Yacht-Geschäft. Privilège ist weltweit in Preis und Qualität die Nummer eins“, so CEO Dr. Jens Gerhardt. Zudem sei der Deal ein wichtiger Faktor, um die EBITDA-Marge auf 10 bis 12 % zu steigern. Im Financial.de-Interview spricht der Konzernlenker über die aktuellsten Trends im Yacht-Geschäft, die laufende Barkapitalerhöhung sowie die Weltpremieren in Cannes.

GBC-Fokusbox

Fonds Research 2019: S.E.A. Asian High Yield Bond bietet attraktive Investitionschance

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter auch den S.E.A. Asian High Yield Bond (ISIN: LU1138637738), der eine gute Anlagechance anbietet mit einer Strategie, die kaum reproduzierbar ist. Insbesondere vor dem Hintergrund des anhaltenden Niedrigzinsniveaus sehen wir den Anleihefonds als äußerst attraktive Investitionschance, um nachhaltige und volatilitätsarme Renditen zu erzielen. Wir haben den S.E.A. Asian High Yield Bond mit 4 von 5 Falken eingestuft.

News im Fokus

Vonovia SE: Response to the Berlin Government's Plans for an Absolute Rent Ceiling in Berlin

26. August 2019, 06:30

Aktueller Webcast

SeaChange Corporation

Second Quarter 2020 Earnings Conference Call

29. August 2019

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Buy

23. August 2019